KCNQ2

Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics

Retrieved on: 
Tuesday, October 10, 2023
Steps, National Society of Genetic Counselors, NYSE, Classification, Sibling, Breast cancer, Health, Genetic counseling, CGC, Gene, Phenotype, Research, AGS, Conference, Fiat 500X, NSGC, DNA, DSM-IV codes, Boston Children's Hospital, MPH, KCNQ2, Aicardi–Goutières syndrome, ACMG, Prostate cancer, National Society, RNA, Effectiveness, Risk, Cancer, Heart, Population genomics, University of Connecticut Health Center, SAN, End Stage Renal Disease Program, Senior counsel, Huntington's disease, Uncertainty, Family, LCGC, Genetic, VUS, UPMC Children's Hospital of Pittsburgh, Hospital, PMS2, Genetics, Patient, Genetic testing, HD, Outline of counseling, Pharmaceutical industry, Nursing, Communications satellite, Medical imaging, Birth control, Vaccine, Woman, Invitae

SAN FRANCISCO, Oct. 10, 2023 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are showcasing their work next week at the National Society of Genetic Counselors (NSGC) 42nd Annual Conference in Chicago that highlights the importance of genetics-informed patient care. In addition to its research presentations, the company will present the Heart of Genetic Counseling Award which recognizes excellence in the field of genetic counseling.

Key Points: 
  • In addition to its research presentations, the company will present the Heart of Genetic Counseling Award which recognizes excellence in the field of genetic counseling.
  • "The NSGC Annual Conference is a great opportunity for Invitae researchers to share cutting-edge scientific advancements with genetic counselors who play an integral role in genetics-informed patient care," said Robert Nussbaum, M.D., chief medical officer at Invitae.
  • Invitae joins NSGC in presenting the Heart of Genetic Counseling Award – honoring excellence in genetic counseling and patient care as recognized by patients.
  • To learn more about Invitae's presence at the NSGC 42nd Annual Conference or the Heart of Genetic Counseling Award, visit our website .

Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck

Retrieved on: 
Monday, May 8, 2023
Epilepsy, DSM-IV codes, POC, Lundbeck, Central nervous system, SVP, Therapy, KCNQ2, Doctor of Philosophy, CNS, Pharmaceutical industry

The agreement focuses on activators of KCNQ2, an ion channel that has been clinically validated as a target for the treatment of epilepsy.

Key Points: 
  • The agreement focuses on activators of KCNQ2, an ion channel that has been clinically validated as a target for the treatment of epilepsy.
  • Clinical findings suggest that activation of KCNQ2 channels may provide treatment options for other types of neurological disorders including rare forms of epilepsy.
  • Under the agreement, Neuro3 will receive a worldwide license for intellectual property covering two clinical stage and one pre-clinical stage KCNQ2 activator programs and will be responsible for their further development through clinical proof-of-concept (PoC).
  • Following the completion of the PoC studies, Lundbeck has the option to co-develop and co-commercialize with Neuro3.

Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 1, 2023
KCNQ2, Mount Sinai, Patient, MADRS, Seizure, SCN8A, DBP, Grammatical mood, Channel modulator, Icahn School of Medicine at Mount Sinai, MRI, Ageing, Epilepsy, Depression, Neurocrine Biosciences, MDD, MPC, DSM-IV codes, FOS, OLE, EPIK, Magnetic resonance, SLC6A1 epileptic encephalopathy, Safety, Webcast, Research, Anhedonia, Physician, ID, Pharmaceutical industry, Cryptocurrency, Xenon

BURNABY, British Columbia, March 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • BURNABY, British Columbia, March 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.
  • Topline results from the X-NOVA study are anticipated in the third quarter of this year.
  • No revenue was recognized in the fourth quarter of 2022, and $9.4 million for the year ended 2022, compared to $3.7 million and $18.4 million for the same periods in 2021, respectively.
  • Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its fourth quarter and full year 2022 results.

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023

Retrieved on: 
Monday, January 9, 2023
OLE, Ageing, SCN8A, Depression, Seizure, Icahn School of Medicine at Mount Sinai, Safety, FDA, FOS, MADRS, MPC, MDD, NDA, Grammatical mood, DBP, EPIK, Patient, Neurocrine Biosciences, Epilepsy, MRI, KCNQ2, Anhedonia, Magnetic resonance, Neurocrine, Mount Sinai, Medical imaging, Pharmaceutical industry, Xenon

BURNABY, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined recent progress in its clinical programs and key milestones for 2023.

Key Points: 
  • BURNABY, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined recent progress in its clinical programs and key milestones for 2023.
  • Xenon has initiated a Phase 3 clinical trial, called X-ACKT, to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic clonic seizures (PGTCS).
  • The primary efficacy endpoint is the MPC in monthly PGTCS frequency from baseline through the DBP of XEN1101 compared to placebo.
  • Pursuant to the terms of the agreement, Xenon has the potential to receive certain clinical, regulatory, and commercial milestone payments, as well as future sales royalties.

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)

Retrieved on: 
Friday, December 2, 2022
Dravet syndrome, ASMS, Epilepsy, COVID-19, Safety, MPC, Music City Center, National Primate Research Exhibition Hall, Science, OLE, Urinary retention, Outline, Research, Clinical trial, American Epilepsy Society, Therapy, Convention, Poster, DBP, Patient, Disease, Security (finance), Annual general meeting, FOS, AES, Efficacy, Seizure, KCNQ2, EPIK, SD, Drug Quality and Security Act, Pharmaceutical industry, Medical imaging, Xenon

BURNABY, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2022). In addition, the Company is presenting results from the open label extension (OLE) and sub-analyses of data from the XEN1101 Phase 2b X-TOLE clinical trial.

Key Points: 
  • Mr. Ian Mortimer, Xenons President and Chief Executive Officer stated, We continue to advance our portfolio of neurology-focused programs.
  • We also look forward to meeting with leading epileptologists, including Xenon trial investigators, as well as patient advocacy groups at this important meeting.
  • We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 8, 2022
Investor, GLOBE, Review, OLE, Private Securities Litigation Reform Act, Icahn School of Medicine at Mount Sinai, KCNQ2, PIN, MPC, DBP, Retigabine, MRI, Adult, Seizure, SCN8A, U.S. Securities and Exchange Commission, Depression, Mount Sinai, Nasdaq, Research, Epilepsy, MADRS, Magnetic resonance, KCNQ, COVID-19, Securities Act of 1933, MDD, Alignment, FOS, NASDAQ, Neurocrine, Safety, Securities Exchange Act of 1934, Anhedonia, Grammatical mood, Clinical trial, Channel modulator, EPIK, Physician, Patient, Therapy, Security (finance), Drug Quality and Security Act, NDA, Ageing, FDA, Neurocrine Biosciences, Income, Pharmaceutical industry, Xenon

BURNABY, British Columbia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • BURNABY, British Columbia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  • In June 2022, Xenon announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food & Drug Administration (FDA).
  • Xenon will host a conference call and audio webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its third quarter results and to provide a corporate update.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

QurAlis Presents at ALS Drug Development Summit 2022

Retrieved on: 
Wednesday, May 25, 2022
Dementia, FTD, Death, Phenotype, KCNQ2, Disease, Neurodegeneration, Drug development, Parkinson's disease, RNA splicing, Motor neuron, Gene, Alzheimer's disease, GWAS, Cytoplasm, Patient, Multimedia, View, Paralysis, Amyotrophic lateral sclerosis, Research, Frontotemporal dementia, Genetics, Harvard University, Biomarker, KvLQT2, Human, Mouse, RNA, HIV disease progression rates, Pathology, Maintenance, Therapy, CMO, Peripheral neuropathy, Harvard Medical School, STMN2, Electrophysiology, ALS, CEO, Pharmaceutical industry, Medical device, Medical imaging, Agriculture, Golgi

CAMBRIDGE, Mass., May 25, 2022 /PRNewswire/ -- QurAlis Corporation, a biotech company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced that Kasper Roet, Ph.D., founder and chief executive officer (CEO) and Angela Genge, M.D., chief medical officer (CMO), will deliver presentations at the ALS Drug Development Summit being held May 24-26, 2022 in Boston, Massachusetts.

Key Points: 
  • "The ALS Drug Development Summit brings together ALS experts, researchers, and industry leaders to discuss recent clinical developments, research and development trends, and breakthrough innovations to transform ALS drug development.
  • "Biomarkers are critical to the successful development of therapeutics for patients with ALS.
  • For information about the ALS Drug Development Summit, visit www.als-drug-development.com .
  • QurAlis' proprietary platforms and unique biomarkers enable the design and development of drugs that act directly on disease-causing genetic alterations.

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022

Retrieved on: 
Monday, January 10, 2022
Xenon, Seizure, Safety, MDD, Patient, Lists of diseases, Adult, Epilepsy, Mount, Nasdaq, FDA, GLOBE, KCNQ2, Pharmaceutical industry

BURNABY, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestones for 2022.

Key Points: 
  • BURNABY, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestones for 2022.
  • Pursuant to the terms of the agreement, Xenon has the potential to receive certain clinical, regulatory, and commercial milestone payments, as well as future sales royalties.
  • Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 10, 2021
Cav2.1, Seizure, Clinical trial, Depression, Security (finance), Nerve block, Food, Securities Exchange Act of 1934, COVID-19, Flunarizine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, XEN402, Therapy, Anhedonia, Foot, Drug Quality and Security Act, EPIK, Webcast, Fast Track, Safety, Adolescence, Epilepsy, Method, Research, Securities Act of 1933, U.S. Securities and Exchange Commission, Icahn School of Medicine at Mount Sinai, Time, Patient, FDA, Adult, Orphan, Private Securities Litigation Reform Act, Mount Sinai, Investor, KCNQ2, MDD, European Commission, Income, Nerve, Sale, SCN8A, Magnetic resonance imaging, Magnetic resonance, Neurocrine Biosciences, Ageing, Idiopathic generalized epilepsy, Lists of diseases, KCNQ, CNS, Reward, Royal commission, IND, Pharmaceutical industry

BURNABY, British Columbia, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • For the quarter ended September 30, 2021, Xenon reported total revenue of $8.1 million, compared to $6.6 million for the same period in 2020.
  • Net loss for the quarter ended September 30, 2021 was $15.4 million, compared to $8.9 million for the same period in 2020.
  • Xenon will host a conference call and live audio webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the third quarter results and provide a corporate update.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

Global Epilepsy Pipeline Landscape Report 2021: Comprehensive Insights for 70+ Companies and 70+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021
Health, Pharmaceutical, A2, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CNS, Clinical trial, News, Protocol, Therapy, ODD, COMP, IDH1, Pharmacokinetics, IIA, Lists of diseases, II, Review, Research, Mergers and acquisitions, Channel modulator, PAM, Central nervous system disease, Cannabidiol, Committee, European Medicines Agency, GW Pharmaceuticals, A3, FDA, Fast Track, Patient, GABAA, Adult, Lennox–Gastaut syndrome, Ganaxolone, Ageing, Lorazepam, Status epilepticus, KCNQ2, Photosensitive epilepsy, ES, Dravet syndrome, Safety, Seizure, Lists of World Heritage Sites, GABAergic, A5, EMA, Discovery, Pharmaceutical industry

This Epilepsy - Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Key Points: 
  • This Epilepsy - Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Epilepsy R&D.
  • The therapies under development are focused on novel approaches to treat/improve Epilepsy.
  • This segment of the Epilepsy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.